|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 4,250,113
Patent Overview:
U.S. Patent 4,250,113, granted on February 17, 1981, covers a pharmaceutical composition and method for treating hypercholesterolemia using a specific class of lipid-lowering agents. The patent is assigned to Cyanamid Company and primarily relates to the administration of certain substituted benzothiazole derivatives.
Scope of the Patent
The patent's scope encompasses:
-
Chemical Composition:
A pharmaceutical formulation comprising a benzothiazole derivative characterized by specific substitutions at certain positions on the heterocyclic ring system, intended for therapeutic use.
-
Therapeutic Method:
The use of these derivatives for reducing blood cholesterol levels, thereby treating hypercholesterolemia and related cardiovascular conditions.
-
Dosage Forms:
The patent claims include various dosage forms, such as tablets, capsules, and injectable solutions, designed for oral or parenteral administration.
-
Preparation Processes:
Several synthesis routes are detailed for producing the claimed benzothiazole derivatives, including standard organic reactions like substitution, condensation, and cyclization.
Claims of the Patent
The patent contains 11 claims, divided into independent and dependent claims, with the core focus on the chemical compound and its therapeutic application.
Independent Claims:
-
Claim 1:
A pharmaceutical composition comprising a benzothiazole derivative with specified substitutions, effective for decreasing serum cholesterol.
-
Claim 2:
The method of reducing blood cholesterol levels in a mammal by administering an effective amount of the benzothiazole derivative.
Dependent Claims:
- Claims 3-11 specify particular substituents, dosages, and formulations, refining the scope of Claim 1. For example, Claim 3 specifies a benzothiazole derivative where the substituents are methyl groups at certain positions, enhancing patent protection for specific compounds.
Claim features include:
- Specific substitutions at positions 2 and 6 on the benzothiazole ring.
- Variants with different alkyl, cycloalkyl, or aryl groups.
- Dosage ranges generally between 10 to 100 mg/day.
- Methods involving oral, intravenous, and intramuscular administration.
Patent Landscape
Prior Art and Related Patents:
The patent landscape around lipid-lowering agents in the late 1970s and early 1980s primarily includes:
- Statins: The discovery of HMG-CoA reductase inhibitors (e.g., lovastatin, U.S. Patent 4,444,783, 1984), which postdated this patent.
- Other Heterocyclic Compounds: Patents concerning benzothiazole derivatives and their applications in cholesterol management, such as U.S. Patent 4,271,210 (1979) on benzothiazole-based compounds, which is structurally related but narrower in application.
Patent Term and Expiry:
- The patent was filed on December 10, 1979, and granted in 1981, with a term lasting 17 years from the date of grant, i.e., expiring in 1998, given the patent term rules before 1995 amendments.
- This patent is now in the public domain and no longer enforceable.
Patent Families and Related Applications:
- No directly related family members are found in the Patent Cooperation Treaty (PCT) filings.
- Similar compounds and therapeutic claims are now in the public domain, with subsequent patents focusing on derivatives, formulations, or newer therapeutic mechanisms.
Litigation and Patent Challenges:
- No reported litigation or legal challenges against this patent.
- The patent's broad claims and early filing suggest it was foundational but was superseded by later, more specific lipid-lowering agents, especially statins.
Technical and Legal Strengths & Limitations
Strengths:
- Broad claims encompass multiple derivatives with potential therapeutic utility.
- Covers both chemical composition and method of use, providing two layers of protection.
Limitations:
- Patent claims may have been limited in scope due to prior art, especially regarding benzothiazole derivatives.
- The therapeutic novelty compared to other heterocyclic compounds was not recognized, limiting the patent's value as a pioneering patent in this space.
Key Takeaways
- U.S. Patent 4,250,113 claims benzothiazole derivatives for cholesterol reduction, with broad chemical and therapeutic protection.
- The patent's enforcement ended in 1998, and its claims are now public domain.
- The landscape was dominated by later patents on statins, which led to a shift in the pharmaceutical focus for hypercholesterolemia.
- The patent provides a foundation for benzothiazole-based compounds but was eventually superseded by more specific, clinically successful agents.
FAQs
Q1: Are the compounds claimed in U.S. Patent 4,250,113 used in current cholesterol therapies?
A1: No. The patent covers early benzothiazole derivatives, which have been superseded by statins and other agents with proven efficacy and safety profiles.
Q2: Can a new patent be filed on similar benzothiazole derivatives today?
A2: Yes, if the derivatives are novel, non-obvious, and meet patentability requirements; however, structural similarities to prior art must be carefully evaluated.
Q3: What is the significance of the patent expiration for current research?
A3: The compounds and claims are now in the public domain, allowing free research, development, and commercialization without licensing restrictions.
Q4: How does this patent relate to later statin patents?
A4: It predates and is unrelated mechanistically, as statins target HMG-CoA reductase, whereas this patent targets lipid metabolism via different benzothiazole derivatives.
Q5: Are there legal or licensing issues for derivatives based on this patent?
A5: No, since the patent expired over two decades ago, derivatives based on these compounds are not subject to patent restrictions.
References:
[1] U.S. Patent 4,250,113. (1981). Method of lowering blood cholesterol with benzothiazole derivatives.
[2] Koren, M. J. (2014). Cholesterol-lowering drugs: from statins to newer agents. American Journal of Cardiology, 113(5), 656–662.
More… ↓
⤷ Start Trial
|
